Skip to main content
. 2016 Nov 18;8(1):430–443. doi: 10.18632/oncotarget.13440

Figure 6. Pretreatment of neuroblastoma cells with fosaprepitant synergizes with cytotoxic chemotherapy.

Figure 6

A+B Synergy between fosaprepitant and doxorubicin (A) and etoposide (B) was quantified by Combination Index (CI) analysis vs. fraction affected using CompuSyn (http://www.combosyn.com/). By this method, CI < 1 indicates synergy; CI = 1 indicates an additive effect; and CI > 1 indicates antagonism. Synergy was calculated based on MTT assays of IMR5 cells: i. co-treated with fosaprepitant and doxorubicin (A) or etoposide (B) for 48 hours (left), ii. treated with fosaprepitant for 24 hours followed by 24 hours of doxorubicin (A) or etoposide (B) treatment (middle) or iii. treated with doxorubicin (A) or etoposide (B) for 24 hours followed by fosaprepitant treatment for 24 hours (right).